Alpine Immune Sciences Inc (NASDAQ:ALPN) Expected to Announce Quarterly Sales of $280,000.00

Equities analysts expect Alpine Immune Sciences Inc (NASDAQ:ALPN) to post sales of $280,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Alpine Immune Sciences’ earnings. The lowest sales estimate is $250,000.00 and the highest is $300,000.00. The firm is expected to report its next earnings results on Monday, March 16th.

According to Zacks, analysts expect that Alpine Immune Sciences will report full-year sales of $1.03 million for the current year, with estimates ranging from $860,000.00 to $1.16 million. For the next fiscal year, analysts forecast that the firm will post sales of $1.10 million, with estimates ranging from $1.00 million to $1.20 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its earnings results on Wednesday, November 13th. The biotechnology company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.06. The company had revenue of $0.29 million during the quarter, compared to analyst estimates of $0.38 million.

A number of research analysts have recently commented on ALPN shares. Zacks Investment Research upgraded Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research note on Thursday, November 28th. Piper Jaffray Companies reduced their price objective on Alpine Immune Sciences to $8.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 13th. They noted that the move was a valuation call. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $9.31.

A number of hedge funds and other institutional investors have recently modified their holdings of ALPN. Renaissance Technologies LLC raised its holdings in Alpine Immune Sciences by 10.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,261 shares of the biotechnology company’s stock valued at $447,000 after buying an additional 10,400 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Alpine Immune Sciences during the 2nd quarter worth approximately $90,000. Vanguard Group Inc. grew its holdings in Alpine Immune Sciences by 67.7% during the 2nd quarter. Vanguard Group Inc. now owns 202,582 shares of the biotechnology company’s stock worth $853,000 after acquiring an additional 81,800 shares during the last quarter. Finally, Hikari Power Ltd grew its holdings in Alpine Immune Sciences by 52.9% during the 3rd quarter. Hikari Power Ltd now owns 185,587 shares of the biotechnology company’s stock worth $735,000 after acquiring an additional 64,224 shares during the last quarter. Institutional investors and hedge funds own 46.80% of the company’s stock.

Shares of NASDAQ:ALPN traded up $0.01 during trading on Friday, hitting $3.01. 1,474 shares of the company were exchanged, compared to its average volume of 28,149. The business’s 50 day moving average is $2.89 and its 200-day moving average is $3.98. The company has a market capitalization of $55.58 million, a P/E ratio of -1.15 and a beta of 1.79. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.47. Alpine Immune Sciences has a 1-year low of $2.25 and a 1-year high of $8.24.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.

Read More: How Do Front-End Loads Impact an Investment?

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with's FREE daily email newsletter.